D
D. Hendler
Researcher at University of Paris
Publications - 4
Citations - 3741
D. Hendler is an academic researcher from University of Paris. The author has contributed to research in topics: Oxaliplatin & Medicine. The author has an hindex of 1, co-authored 2 publications receiving 3603 citations.
Papers
More filters
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Journal ArticleDOI
Tilsotolimod exploits the TLR9 pathway to promote antigen presentation and Type 1 IFN signaling in solid tumors: A Multicenter International Phase I/II trial (ILLUMINATE-101).
Hani M. Babiker,Erkut Borazanci,Vivek Subbiah,Sanjiv S. Agarwala,Alain Algazi,Jacob Schachter,Michal Lotem,Corinne Maurice-Dror,D. Hendler,S. Rahimian,Hans Minderman,Cara Haymaker,Daruka Mahadevan,Chantale Bernatchez,Ravi Murthy,Rolf Hultsch,Nadia Caplan,Gregory Woodhead,Charles Hennemeyer,Srinivas K. Chunduru,Peter M. Anderson,Adi Diab,Igor Puzanov +22 more
TL;DR: Overall, tilsotolimod monotherapy was generally well tolerated and induced rapid, robust alterations in the tumor microenvironment.
Journal ArticleDOI
First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel
Itamar Averbuch,S. Salman,Noa Shtamper,Ilana Doweck,Aron Popovtzer,Gal Markel,D. Hendler,Inbar Finkel,Assaf Moore,Eyal Fenig,Tarek Taha,Kamel Mhameed,N. Kurman,Salem Billan +13 more
TL;DR: In this article , the authors presented the Israeli experience with PD-1 inhibitors for the treatment of loco-regionally advanced or metastatic cSCC in a diverse and elderly population, with or without the addition of radiotherapy.
Leucovorin a nd F luorouracil W ith o r W ithout O xaliplatin as F irst-Line T reatment i n A dvanced C olorectal C ancer
A. de Gramont,Arie Figer,Matthew T. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,Hernán Cortés-Funes,A. Cervantes,Gilles Freyer,Demetris Papamichael,N Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progressionfree survival with acceptable tolerability and maintenance of QoL.